FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions relates to compositions causing specific response of cytotoxic T-lymphocytes (CTL) against T-cell epitopes in mammal organism, which include lymphopenia-causing compound, molecule possessing selective affinity to specialised antigen-presenting cells (APC), where said molecule is bound with said T-cell epitope, and, possibly, pharmaceutically acceptable carrier. Compositions can also contain adjuvant.
EFFECT: by means of compositions achieved are efficient anti-infection or anti-tumour actions.
20 cl, 10 dwg, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT PROTEIN CARRYING HUMAN PAPILLOMA VIRUS EPITOPES, PROTEIN EMBEDDED ADENYLATECYCLASE OR ITS FRAGMENT, ITS THERAPEUTIC APPLICATION | 2005 |
|
RU2441022C2 |
| CyaA-CARRIED POLYPEPTIDE (VERSIONS) AND USE TO INDUCE BOTH THERAPEUTIC AND PROPHYLACTIC IMMUNE RESPONSES | 2012 |
|
RU2668795C2 |
| MUTANT POLYPEPTIDES SUAA AND POLYPEPTIDE DERIVATIVES SUITABLE FOR DELIVERY OF IMMUNOGENIC MOLECULES IN CELL | 2010 |
|
RU2585216C2 |
| METHOD FOR PRODUCTION OF IN VITRO POPULATIONS OF ACTIVATED ANTIGENSPECIFIC ANTITUMOR-TUMOR CYTOTOXIC T-LYMPHOCYTES SPECIFIC TO TUMOR-ASSOCIATED ANTIGEN EPITOPES | 2016 |
|
RU2619186C1 |
| POLYEPITOPE ANTI-TUMOUR VACCINE STRUCTURE CONTAINING EPITOPES OF TUMOR-ASSOCIATED ANTIGENS, PHARMACEUTICAL COMPOSITION AND ITS APPLICATION FOR STIMULATING SPECIFIC ANTI-TUMOR IMMUNE RESPONSE | 2016 |
|
RU2684235C2 |
| TEM8 PEPTIDES AND VACCINES CONTAINING THEM | 2008 |
|
RU2498993C2 |
| IMMUNOSTIMULATING COMPOSITIONS | 2016 |
|
RU2732118C2 |
| METHOD OF PRODUCING ANTIGEN-SPECIFIC CYTOTOXIC CELLS HAVING ACTIVITY AGAINST BREAST CANCER CELLS | 2013 |
|
RU2596920C2 |
| METHODS OF PREDICTING THE APPLICABILITY OF DISEASE-SPECIFIC AMINO ACID MODIFICATIONS FOR IMMUNOTHERAPY | 2018 |
|
RU2799341C2 |
| FUSION PROTEINS FOR APPLICATION AS IMMUNOGENIC AMPLIFYING AGENTS TO INDUCE ANTIGEN-SPECIFIC T-CELL RESPONSE | 2013 |
|
RU2631002C2 |
